Hayden E. Klein

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association (ADA), describes the ADA's efforts to elevate the conversation about the impact of diabetes on kidney disease.

The prognosis was worse in patients with basic dementia or Alzheimers disease as well as chronic obstructive pulmonary disease or asthma.

Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, explains how different populations are at different risk for breast cancer and the importance of informed screening.

The study found that cough severity and cough-related quality of life were not related to the severity of bronchial hyperresponsiveness in nonsmoking adults with cough-variant asthma.

The forum will focus on PBMs’ disproportionate influence over the treatment of patients with cancer, as well as drug pricing and patient cost sharing.

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, explains the Health Equity Now initiative and how it shines a light on health disparities.

Ian J. Neeland, MD, FACC, FAHA, is co-director of the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease for University Hospitals Harrington Heart & Vascular Institute and director of the UH Center for Cardiovascular Prevention, in the Cleveland, Ohio, area. He summarized a talk he gave at the 2021 AHA Scientific Sessions, “Disrupted Sleep in Diabetic Vascular Complications."

Michael Dorsch, PharmD, MS, describes just-in-time adaptive interventions and microrandomized trials in mHealth, which he discussed at the 2021 American Heart Association Scientific Sessions.

Biological markers collected early in the disease course of rheumatoid arthritis could help improve patient management, researchers said.

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, explains why clinical trials need to be inclusive and how the Health Equity Now initiative is working to recruit more diverse populations with diabetes.

Access to antiretroviral treatment was not disrupted, despite decreased in-person services during the pandemic.

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, discusses COVID-19 vaccinations among people with diabetes as they have been disproportionally affected by the pandemic.

If FDA approved for children, secukinumab (Cosentyx) will be the first biologic treatment for children in the US living with enthesitis-related arthritis.

The most common health care disruption found in the study was the replacement of face-to-face consultations with over-the-phone appointments.

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association (ADA), talks about the "old-fashioned" finger stick requirement for continuous glucose monitoring.

The review found an association between systemic inflammatory disorders and increased risk of cardiovascular disease, encouraging discussions with patients regarding statin therapy.

Multiple nationally representative surveys found that approximately 1 in 3 grade 12 students vaped cannabis in 2018 alone.

As time goes on, we're finding out more and more benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors, said Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association.

Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA), discusses the most important takeaways from recent guidance on type 1 diabetes from the ADA and European Association for the Study of Diabetes (EASD).

The WISDOM study—Women Informed to Screen Depending On Measures of risk—was launched to test a personalized approach to screening compared to annual mammograms. Funmi Olopade, MD, FACP, is a professor of Medicine and Human Genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, and a co-investigator of WISDOM. She discussed how the COVID-19 pandemic actually helped increase participation in the WISDOM study and what it means for future trials.

Researchers hope these findings help develop methods to assess cognitive function in patients with rheumatoid arthritis.

While sales have gone up, the research does not directly show whether there is an increase in people smoking cigarettes.

The WISDOM study—Women Informed to Screen Depending On Measures of risk—was launched to test a personalized approach to screening compared to annual mammograms. Funmi Olopade, MD, FACP, is a professor of Medicine and Human Genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, and a co-investigator of WISDOM. She is an expert on understanding the etiology and genomic basis of cancer progression in diverse populations and has published extensively on both genetic and non-genetic risk factors for breast cancer. She discussed overcoming early challenges of low enrollment of Black women in the study.

The low-dose tablet will help pediatric patients weighing between 14 kg and 25 kg who are virologically suppressed or new to antiretroviral therapy.

Some alcohol, but not more than 1 drink per day, was linked to a 55% lower risk of type 2 diabetes in women with a history of gestational diabetes.

The task force determined that potential harms of adults aged 60 and older using aspirin for prevention outweighed the benefits.

The study found that a combination of the Chinese symptom-based questionnaire and microspirometry could provide the most efficient and cost-effective way of identifying patients who need treatment for COPD.

Research presented during IDWeek 2021 showed data on V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine.

Patients with T2D had elevated blood glucose levels but there were no notable differences in levels between surviving and non-surviving patients with T2D.

New research presented at the AHA Hypertension Scientific Sessions 2021 showed that men aged 20 to 49 years and women 70 and older both had a greater risk of hypertension.